Epitopea is targeting a new class of untapped tumor-specific antigens, which are known as CryptigenTM TSAs, that are broadly shared across multiple patients with the same tumor type. 

The company is backed by leading life science investors including Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital, Le Fonds de Solidarité FTQ, Investissement Québec, adMare BioInnovations, Jonathan Milner, the Harrington Discovery Institute, IRICoR and Novateur Ventures. As of Q4 2024, the company has raised financing of more than USD $45 million. Epitopea was founded in 2021 and consists of sister companies based in Cambridge, UK and in Montreal, Canada.